X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20993) 20993
Newsletter (1522) 1522
Newspaper Article (376) 376
Magazine Article (123) 123
Book / eBook (70) 70
Transcript (32) 32
Book Chapter (23) 23
Web Resource (6) 6
Reference (5) 5
Dissertation (4) 4
Conference Proceeding (3) 3
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15168) 15168
mycoses (8454) 8454
male (7101) 7101
bacterial infections and mycoses (6963) 6963
female (6631) 6631
mycoses - drug therapy (5872) 5872
antifungal agents - therapeutic use (4897) 4897
adult (4851) 4851
microbiology (4817) 4817
middle aged (4637) 4637
infectious diseases (3902) 3902
health aspects (3476) 3476
antifungal agents (3448) 3448
aged (3188) 3188
animals (2942) 2942
research (2930) 2930
biochemical phenomena, metabolism, and nutrition (2809) 2809
pharmacology & pharmacy (2670) 2670
microbial sensitivity tests (2583) 2583
infections (2535) 2535
infection (2431) 2431
care and treatment (2245) 2245
mycoses - microbiology (2182) 2182
adolescent (2176) 2176
drug therapy (2065) 2065
risk factors (2006) 2006
research article (2001) 2001
treatment outcome (1980) 1980
diagnosis (1901) 1901
immunology (1861) 1861
bacteria (1849) 1849
epidemiology (1794) 1794
child (1785) 1785
anti-bacterial agents - therapeutic use (1748) 1748
antifungal agents - pharmacology (1684) 1684
analysis (1640) 1640
medicine (1627) 1627
mycoses - diagnosis (1520) 1520
retrospective studies (1514) 1514
polycyclic compounds (1482) 1482
antifungal agents - administration & dosage (1468) 1468
mortality (1456) 1456
amphotericin b - therapeutic use (1426) 1426
fungi (1421) 1421
medical research (1353) 1353
anti-bacterial agents - pharmacology (1352) 1352
antibiotics (1346) 1346
fluconazole (1333) 1333
therapy (1322) 1322
dermatology (1282) 1282
fungal infections (1254) 1254
mycology (1252) 1252
young adult (1245) 1245
medicine, experimental (1206) 1206
drug resistance (1202) 1202
voriconazole (1194) 1194
transplantation (1190) 1190
child, preschool (1113) 1113
mycoses - prevention & control (1095) 1095
cancer (1091) 1091
mycoses - etiology (1072) 1072
aged, 80 and over (1058) 1058
drug therapy, combination (1050) 1050
mice (1045) 1045
aspergillosis (1017) 1017
amphotericin-b (1012) 1012
itraconazole (997) 997
patients (982) 982
immunocompromised host (968) 968
mycoses - complications (958) 958
infectious and parasitic diseases (948) 948
amphotericin b (888) 888
mycoses - epidemiology (884) 884
prevalence (882) 882
antifungal agents - adverse effects (869) 869
drug resistance in microorganisms (851) 851
candidiasis - drug therapy (844) 844
susceptibility (844) 844
infant (830) 830
bacterial infections - drug therapy (829) 829
tuberculosis (824) 824
hospitals (822) 822
internal medicine (800) 800
medicine, general & internal (799) 799
physical fitness (772) 772
hematology (766) 766
drugs (762) 762
medicine & public health (759) 759
onychomycosis (752) 752
multidisciplinary sciences (751) 751
resistance (749) 749
fungi - drug effects (747) 747
disease (745) 745
risk-factors (729) 729
pediatrics (726) 726
prospective studies (714) 714
children (712) 712
triazoles - therapeutic use (712) 712
candidiasis (706) 706
science (690) 690
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (27) 27
Online Resources - Online (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Law (Bora Laskin) - Stacks (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21747) 21747
German (391) 391
French (276) 276
Spanish (217) 217
Japanese (204) 204
Russian (114) 114
Chinese (81) 81
Italian (68) 68
Polish (63) 63
Turkish (37) 37
Dutch (24) 24
Czech (23) 23
Portuguese (23) 23
Hungarian (16) 16
Romanian (15) 15
Danish (8) 8
Norwegian (8) 8
Finnish (7) 7
Swedish (6) 6
Hebrew (4) 4
Serbian (4) 4
Slovak (4) 4
Croatian (3) 3
Ukrainian (3) 3
Arabic (2) 2
Bulgarian (2) 2
Greek (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet infectious diseases, ISSN 1473-3099, 2014, Volume 14, Issue 11, pp. 1136 - 1149
... tuberculosis , and multiazole-resistant fungi has focused attention on investments into development of new drugs and treatment regimens... 
Infectious Disease | INFECTIOUS DISEASES | INFLUENZA-A | ASPERGILLUS-FUMIGATUS | IN-VITRO | VIRUS-INFECTION | A DOUBLE-BLIND | OPEN-LABEL | CRITICALLY-ILL PATIENTS | T-CELLS | SYNDROME CORONAVIRUS | H1N1 VIRUS | Mycoses - epidemiology | Virus Diseases - epidemiology | Biological Therapy - methods | Biological Therapy - trends | Humans | Drug Resistance, Viral | Drug Resistance, Bacterial | Mycoses - microbiology | Virus Diseases - virology | Antifungal Agents - therapeutic use | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Virus Diseases - drug therapy | Respiratory Tract Infections - virology | Drug Resistance, Fungal | Bacterial Infections - microbiology | Drug Therapy - trends | Antifungal Agents - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Bacterial Infections - drug therapy | Drug Discovery - trends | Respiratory Tract Infections - drug therapy | Treatment Outcome | Drug Therapy - methods | Bacterial Infections - epidemiology | Mycoses - drug therapy | Anti-Bacterial Agents - pharmacology | Respiratory Tract Infections - epidemiology | Antiviral agents | Hospitals | Influenza | Mycoses | Development and progression | Bacteria | Cross infection | Nosocomial infections | Drug therapy | Cells | Drug resistance in microorganisms | Severe acute respiratory syndrome | Respiratory agents | Pandemics | Mortality | Respiratory diseases | Viral infections
Journal Article
Haematologica (Roma), ISSN 1592-8721, 2015, Volume 100, Issue 7, pp. 978 - 988
.... Current criteria were created to identify patients with familial hemophagocytic lmyphohistiocytosis in immediate need of immunosuppressive therapy... 
DEFECTS | CHRONIC GRANULOMATOUS-DISEASE | MACROPHAGE ACTIVATION SYNDROME | BONE-MARROW | PERFORIN | HEMATOLOGY | CYTOTOXICITY | DEFICIENCY | TRANSPLANTATION | MANIFESTATIONS | DELETION | Lymphohistiocytosis, Hemophagocytic - pathology | Humans | Child, Preschool | Lymphoproliferative Disorders - complications | Male | Virus Diseases - complications | Virus Diseases - drug therapy | T-Lymphocytes - drug effects | Opportunistic Infections - immunology | Immunologic Deficiency Syndromes - immunology | Child | Infant, Newborn | Lymphohistiocytosis, Hemophagocytic - immunology | Opportunistic Infections - complications | Leishmaniasis - immunology | Virus Diseases - immunology | Bacterial Infections - drug therapy | Lymphohistiocytosis, Hemophagocytic - drug therapy | Europe | Lymphohistiocytosis, Hemophagocytic - diagnosis | Terminology as Topic | Leishmaniasis - drug therapy | Immunoglobulins, Intravenous - therapeutic use | Adolescent | Mycoses - drug therapy | T-Lymphocytes - immunology | Immunologic Deficiency Syndromes - drug therapy | Killer Cells, Natural - drug effects | Mycoses - complications | Mycoses - immunology | Infant | Killer Cells, Natural - pathology | Lymphoproliferative Disorders - immunology | Bacterial Infections - complications | Bacterial Infections - immunology | Killer Cells, Natural - immunology | Adult | Female | Registries | Steroids - therapeutic use | T-Lymphocytes - pathology | Immunologic Deficiency Syndromes - diagnosis | Diagnosis, Differential | Immunologic Deficiency Syndromes - complications | Lymphoproliferative Disorders - diagnosis | Opportunistic Infections - drug therapy | Lymphoproliferative Disorders - drug therapy | Leishmaniasis - complications | Immunologic Factors - therapeutic use
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 1, pp. S25 - S38
Abstract Effective management of invasive fungal infections (IFIs) depends on early individualized therapy that optimizes efficacy and safety... 
Internal Medicine | Therapeutic drug monitoring | Echinocandins | Mucormycosis | Amphotericin B | Triazoles | Hepatotoxicity | DISSEMINATED ZYGOMYCOSIS | IN-VITRO SUSCEPTIBILITIES | BREAKTHROUGH FUNGAL-INFECTIONS | PREEMPTIVE ANTIFUNGAL THERAPY | LIPOSOMAL AMPHOTERICIN-B | CLINICAL-PRACTICE GUIDELINES | CELL TRANSPLANT RECIPIENTS | MEDICINE, GENERAL & INTERNAL | SALVAGE THERAPY | INFECTIOUS-DISEASES-SOCIETY | DRUG-DRUG INTERACTIONS | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Humans | Middle Aged | Mycoses - microbiology | Male | Alanine Transaminase - blood | Antineoplastic Agents - administration & dosage | Echinocandins - administration & dosage | Liver - drug effects | Antineoplastic Agents - adverse effects | Antifungal Agents - pharmacokinetics | Mycoses - metabolism | Adult | Female | Mucormycosis - surgery | Mucormycosis - drug therapy | Alkaline Phosphatase - blood | Myelodysplastic Syndromes - drug therapy | Aspergillosis - drug therapy | Flucytosine - administration & dosage | Liver - metabolism | Risk Factors | Leukemia - drug therapy | Mycoses - surgery | Pneumonia - microbiology | Biomarkers - blood | Bilirubin - blood | Flucytosine - adverse effects | Echinocandins - adverse effects | Pneumonia - drug therapy | Aspartate Aminotransferases - blood | Liver Function Tests - standards | Opportunistic Infections - drug therapy | Mycoses - drug therapy | Immunocompromised Host | Drug Monitoring | Antifungal Agents - administration & dosage | Care and treatment | Mycoses | Diagnosis | Research | Health aspects | Risk factors | Drugs | flucytosine | Pharmacodynamics | Risk groups | Mortality | Antifungal agents | Molds | triazoles | Epidemiology | Radicals | Infection | Lipophilic | hepatotoxicity | Voriconazole | Pharmacokinetics | Posaconazole | Itraconazole
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2015, Volume 60, Issue 9, pp. 1319 - 1325
...) bacteremia is controversial. We compared 14-day mortality of PTZ vs carbapenems as empiric therapy in a cohort of patients with ESBL bacteremia who all received definitive therapy with a carbapenem. Methods... 
Resistance | ESBL | Carbapenem | Piperacillin-tazobactam | Gram-negative | MORTALITY | INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | RISK-FACTORS | gram-negative | KLEBSIELLA-PNEUMONIAE BACTEREMIA | ANTIMICROBIAL THERAPY | ESCHERICHIA-COLI | MICROBIOLOGY | IMMUNOLOGY | INHIBITOR COMBINATIONS | resistance | carbapenem | INTENSIVE-CARE-UNIT | piperacillin-tazobactam | BLOOD-STREAM INFECTIONS | ENTEROBACTERIACEAE | Klebsiella pneumoniae - isolation & purification | Klebsiella pneumoniae - drug effects | Escherichia coli - drug effects | Humans | Middle Aged | Bacteremia - mortality | Male | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Time Factors | Penicillanic Acid - therapeutic use | Female | beta-Lactamases - metabolism | Penicillanic Acid - analogs & derivatives | Klebsiella oxytoca - drug effects | Enterobacteriaceae Infections - microbiology | Bacteremia - drug therapy | Enterobacteriaceae Infections - mortality | Proportional Hazards Models | Survival Rate | Klebsiella oxytoca - isolation & purification | Proteus mirabilis - isolation & purification | Propensity Score | Carbapenems - therapeutic use | Escherichia coli - isolation & purification | beta-Lactamase Inhibitors - therapeutic use | Aged | Proteus mirabilis - drug effects | Cohort Studies | Enterobacteriaceae Infections - drug therapy | Piperacillin - therapeutic use | Care and treatment | Dosage and administration | Tazobactam | Carbapenems | Piperacillin | Bacteremia | and Commentaries
Journal Article
PloS one, ISSN 1932-6203, 2012, Volume 7, Issue 4, p. e35072
H. pylori drug-resistant strains and non-compliance to therapy are the major causes of H... 
POLYUNSATURATED FATTY-ACIDS | INFECTION | MONOGLYCERIDES | MULTIDISCIPLINARY SCIENCES | Gastritis - drug therapy | Gastric Mucosa - microbiology | Mice, Inbred C57BL | Helicobacter pylori - ultrastructure | Gastric Mucosa - pathology | Helicobacter pylori - drug effects | Male | Docosahexaenoic Acids - administration & dosage | Helicobacter Infections - pathology | Docosahexaenoic Acids - pharmacology | Animals | Gastritis - pathology | Helicobacter Infections - drug therapy | Gastritis - microbiology | Anti-Bacterial Agents - pharmacology | Mice | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Unsaturated fatty acids | Helicobacter pylori | Growth | Analysis | Helicobacter infections | Health aspects | Omega-3 fatty acids | Antiulcer drugs | Therapy | Stomach | Disease | Fish oils | Gastric mucosa | Infections | Drug resistance | Docosahexaenoic acid | Fatty acids | Stomach cancer | Inflammatory diseases | Medicine | Studies | Pathology | Immunology | Antibiotics | Ulcers | Biomarkers | Bacteria | In vivo methods and tests | Colonization | Helicobacter Infections/drug therapy | Docosahexaenoic Acids/administration & dosage | Anti-Bacterial Agents/administration & dosage | Helicobacter Infections/pathology | Helicobacter Infections/microbiology | Gastritis/drug therapy | Anti-Bacterial Agents/pharmacology | Bacteriology | Helicobacter pylori/drug effects | Helicobacter pylori/ultrastructure | Gastritis/pathology | Life Sciences | Microbiology and Parasitology | Human health and pathology | Gastritis/microbiology | Infectious diseases | Gastric Mucosa/microbiology | Gastric Mucosa/pathology
Journal Article
Nature Medicine, ISSN 1078-8956, 04/2013, Volume 19, Issue 4, pp. 418 - 420
Co-therapy with rifampicin (RIF) and isoniazid (INH) used to treat tuberculosis in humans frequently causes liver injury... 
MEDICINE, RESEARCH & EXPERIMENTAL | DRUG-INTERACTIONS | GENOTYPE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ERYTHROPOIETIC-PROTOPORPHYRIA | INJURY | LIVER TOXICITY | MODEL | PREGNANE-X-RECEPTOR | CELL BIOLOGY | DISEASE | GENE-EXPRESSION | DEFINES | Antitubercular Agents - adverse effects | Liver - pathology | Receptors, Steroid - metabolism | Humans | Isoniazid - adverse effects | Male | Alanine Transaminase - blood | Drug Therapy, Combination - adverse effects | Rifampin - adverse effects | Liver - drug effects | Heme - biosynthesis | Isoniazid - therapeutic use | Rifampin - therapeutic use | Rifampin - administration & dosage | Chemical and Drug Induced Liver Injury - pathology | Alkaline Phosphatase - blood | Chemical and Drug Induced Liver Injury - etiology | Antitubercular Agents - therapeutic use | Liver - metabolism | Protoporphyrins - biosynthesis | Heme - analysis | Mice, Transgenic | Receptors, Steroid - drug effects | Protoporphyrins - analysis | Liver - chemistry | Isoniazid - administration & dosage | Animals | Chemical and Drug Induced Liver Injury - metabolism | Receptors, Steroid - physiology | Antitubercular Agents - administration & dosage | Mice | Complications and side effects | Transcription factors | Usage | Liver | Analysis | Antitubercular agents | Research | Injuries | Side effects | Pharmacology | Tuberculosis | Drug therapy | Toxicity
Journal Article
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 4/2009, Volume 48, Issue 8, pp. 1042 - 1051
Journal Article